Literature DB >> 20331757

Haemophilic arthropathy of the ankle treated by total ankle replacement: a case series.

A Barg1, A Elsner, D Hefti, B Hintermann.   

Abstract

The standard treatment for end-stage osteoarthritis of the ankle joint in haemophilic patients has been fusion of the ankle joint. Total ankle replacement is still controversial as a treatment option. The objective of this prospective study was to evaluate the mid-term outcome in patients treated with total ankle replacement using an unconstrained three-component ankle implant. Ten haemophilic ankles in eight patients (mean age: 43.2 years, range 26.7-57.5) treated with total ankle replacement were followed up for a minimum of 2.7 years (mean: 5.6, range 2.7-7.6). The outcome was measured with clinical and radiological evaluations. There were no intra- or peri-operative complications. The AOFAS-hindfoot-score increased from 38 (range 8-57) preoperatively to 81 (range 69-95) postoperatively. All patients were satisfied with the results. Four patients became pain free; in the whole patient cohort pain level decreased from 7.1 (range 4-9) preoperatively to 0.8 (range 0-3) postoperatively. All categories of SF-36 score showed significant improvements in quality of life. In one patient, open ankle arthrolysis was performed because of painful arthrofibrosis. For patients with haemophilic osteoarthritis of the ankle joint, total ankle replacement is a valuable alternative treatment to ankle fusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331757     DOI: 10.1111/j.1365-2516.2010.02221.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  14 in total

1.  Osteochondral repair in hemophilic ankle arthropathy: from current options to future perspectives.

Authors:  Roberto Buda; Marco Cavallo; Francesco Castagnini; Enrico Ferranti; Simone Natali; Sandro Giannini
Journal:  Joints       Date:  2016-01-31

Review 2.  Rheumatologic manifestations of benign and malignant haematological disorders.

Authors:  Vinod Ravindran; Parameswaran Anoop
Journal:  Clin Rheumatol       Date:  2011-06-23       Impact factor: 2.980

3.  Long-term results of ankle arthrodesis in children and adolescents with haemophilia.

Authors:  Nicolas de l'Escalopier; Alina Badina; Jean Paul Padovani; Annie Harroche; Laurent Frenzel; Philippe Wicart; Christophe Glorion; Chantal Rothschild
Journal:  Int Orthop       Date:  2017-04-20       Impact factor: 3.075

4.  Can a Three-Component Prosthesis be Used for Conversion of Painful Ankle Arthrodesis to Total Ankle Replacement?

Authors:  Markus Preis; Travis Bailey; Lucas S Marchand; Alexej Barg
Journal:  Clin Orthop Relat Res       Date:  2017-04-19       Impact factor: 4.176

5.  [Total ankle replacement in patients with bleeding disorders].

Authors:  A Barg; K Barg; M Wiewiorski; S W Schneider; M D Wimmer; D C Wirtz; V Valderrabano; G Pagenstert
Journal:  Orthopade       Date:  2015-08       Impact factor: 1.087

6.  Factors Predictive of Early Complications Following Total Ankle Arthroplasty.

Authors:  Christopher Del Balso; Mansur M Halai; Mark D MacLeod; David W Sanders; Abdel Rahman Lawendy
Journal:  Foot Ankle Orthop       Date:  2022-06-14

Review 7.  Ankle hemophilic arthropathy: literature review.

Authors:  Tommaso Greco; Chiara Polichetti; Adriano Cannella; Vincenzo La Vergata; Giulio Maccauro; Carlo Perisano
Journal:  Am J Blood Res       Date:  2021-06-15

8.  Total ankle replacement for treatment of end-stage osteoarthritis in elderly patients.

Authors:  Beat Hintermann; Markus Knupp; Lukas Zwicky; Alexej Barg
Journal:  J Aging Res       Date:  2012-06-05

Review 9.  Optimal management of hemophilic arthropathy and hematomas.

Authors:  Sébastien Lobet; Cedric Hermans; Catherine Lambert
Journal:  J Blood Med       Date:  2014-10-17

10.  Ankle arthroplasty in a patient with bleeding diathesis and the mid-term clinical outcome of the case.

Authors:  Barış Yilmaz; Baran Kömür; Güzelali Özdemir; Nurettin Heybeli
Journal:  Ann Med Surg (Lond)       Date:  2015-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.